HRP20100209T1 - Makrociklički inhibitori virusa hepatitisa c - Google Patents
Makrociklički inhibitori virusa hepatitisa c Download PDFInfo
- Publication number
- HRP20100209T1 HRP20100209T1 HR20100209T HRP20100209T HRP20100209T1 HR P20100209 T1 HRP20100209 T1 HR P20100209T1 HR 20100209 T HR20100209 T HR 20100209T HR P20100209 T HRP20100209 T HR P20100209T HR P20100209 T1 HRP20100209 T1 HR P20100209T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound according
- c6alkyl
- image
- hydrogen
- alkyl
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 2
- 241000711549 Hepacivirus C Species 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 28
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 15
- 239000001257 hydrogen Substances 0.000 claims abstract 13
- -1 C1-C6alkoxy Chemical group 0.000 claims abstract 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 5
- 229910003827 NRaRb Inorganic materials 0.000 claims abstract 4
- 229910052799 carbon Inorganic materials 0.000 claims abstract 4
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 4
- 125000001424 substituent group Chemical group 0.000 claims abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract 2
- 150000001204 N-oxides Chemical class 0.000 claims abstract 2
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims abstract 2
- 125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims abstract 2
- 150000002825 nitriles Chemical group 0.000 claims abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 claims abstract 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000005843 halogen group Chemical group 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003368 amide group Chemical group 0.000 claims 2
- 125000001246 bromo group Chemical group Br* 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 206010054261 Flavivirus infection Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 125000004452 carbocyclyl group Chemical group 0.000 claims 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 229940127073 nucleoside analogue Drugs 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D245/00—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms
- C07D245/04—Heterocyclic compounds containing rings of more than seven members having two nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05107057 | 2005-07-29 | ||
| EP06113097 | 2006-04-25 | ||
| PCT/EP2006/064822 WO2007014927A2 (en) | 2005-07-29 | 2006-07-28 | Macrocyclic inhibitors of hepatitis c virus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20100209T1 true HRP20100209T1 (hr) | 2010-05-31 |
Family
ID=37708968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20100209T HRP20100209T1 (hr) | 2005-07-29 | 2010-04-14 | Makrociklički inhibitori virusa hepatitisa c |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US7659245B2 (me) |
| EP (1) | EP1912981B1 (me) |
| JP (1) | JP5230418B2 (me) |
| KR (1) | KR101083631B1 (me) |
| AP (1) | AP2585A (me) |
| AR (1) | AR057702A1 (me) |
| AT (1) | ATE455775T1 (me) |
| AU (1) | AU2006274866B2 (me) |
| BR (1) | BRPI0614153A2 (me) |
| CA (1) | CA2617103C (me) |
| CY (1) | CY1110008T1 (me) |
| DE (1) | DE602006011905D1 (me) |
| DK (1) | DK1912981T3 (me) |
| EA (1) | EA014188B1 (me) |
| ES (1) | ES2339702T3 (me) |
| GT (1) | GT200600343A (me) |
| HK (1) | HK1116488A1 (me) |
| HR (1) | HRP20100209T1 (me) |
| IL (1) | IL188320A (me) |
| ME (1) | ME01454B (me) |
| MY (1) | MY151026A (me) |
| NO (1) | NO20081075L (me) |
| NZ (1) | NZ564540A (me) |
| PE (1) | PE20070343A1 (me) |
| PL (1) | PL1912981T3 (me) |
| PT (1) | PT1912981E (me) |
| RS (1) | RS51227B (me) |
| SI (1) | SI1912981T1 (me) |
| SV (1) | SV2008002641A (me) |
| TW (1) | TWI387597B (me) |
| UY (1) | UY29704A1 (me) |
| WO (1) | WO2007014927A2 (me) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| WO2005073195A2 (en) | 2004-01-30 | 2005-08-11 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
| TW200745061A (en) | 2005-07-29 | 2007-12-16 | Tibotec Pharm Ltd | Macrocylic inhibitors of hepatitis C virus |
| MY142972A (en) | 2005-07-29 | 2011-01-31 | Tibotec Pharm Ltd | Macrocyclic inhibitors of hepatitis c virus |
| JO2768B1 (en) * | 2005-07-29 | 2014-03-15 | تيبوتيك فارماسيوتيكالز ليمتد | Large cyclic inhibitors of hepatitis C virus |
| PE20070211A1 (es) | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
| DE602006019323D1 (de) | 2005-10-11 | 2011-02-10 | Intermune Inc | Verbindungen und verfahren zur inhibierung der replikation des hepatitis-c-virus |
| US7741281B2 (en) | 2005-11-03 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR20090024834A (ko) | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | Ｃ형 간염 바이러스 복제의 신규 억제제 |
| US7935670B2 (en) | 2006-07-11 | 2011-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| KR101512477B1 (ko) | 2006-07-13 | 2015-04-15 | 아칠리온 파르마세우티칼스 인코포레이티드 | 바이러스 복제 억제제로서 사용되는 4-아미노-4-옥소부타노일 펩티드 |
| US8343477B2 (en) | 2006-11-01 | 2013-01-01 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7888464B2 (en) | 2006-11-16 | 2011-02-15 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8003604B2 (en) | 2006-11-16 | 2011-08-23 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7763584B2 (en) | 2006-11-16 | 2010-07-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP2010510192A (ja) * | 2006-11-17 | 2010-04-02 | テイボテク・フアーマシユーチカルズ・リミテツド | Ｃ型肝炎ウイルスの大環状阻害剤 |
| MX2009008271A (es) * | 2007-02-01 | 2009-08-12 | Tibotec Pharm Ltd | Procesos e intermediarios para la preparacion de un inhibidor de proteasa macrocilico del vhc. |
| CN105254637A (zh) * | 2007-02-08 | 2016-01-20 | 爱尔兰詹森科学公司 | 嘧啶取代的大环抑制剂 |
| ITMI20071616A1 (it) | 2007-08-03 | 2009-02-04 | Cosmo Spa | Processo enzimatico per l'ottenimento di 17-alfa monoesteri del cortexolone e/o suoi 9,11-deidroderivati. |
| JP2010540549A (ja) * | 2007-09-24 | 2010-12-24 | アキリオン ファーマシューティカルズ，インコーポレーテッド | ウイルス複製阻害剤としての尿素含有ペプチド |
| US8383583B2 (en) | 2007-10-26 | 2013-02-26 | Enanta Pharmaceuticals, Inc. | Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors |
| US8426360B2 (en) * | 2007-11-13 | 2013-04-23 | Enanta Pharmaceuticals, Inc. | Carbocyclic oxime hepatitis C virus serine protease inhibitors |
| WO2009070692A1 (en) | 2007-11-29 | 2009-06-04 | Enanta Pharmaceuticals, Inc. | C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors |
| US8202996B2 (en) | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| JPWO2009084695A1 (ja) | 2007-12-28 | 2011-05-19 | カルナバイオサイエンス株式会社 | ２−アミノキナゾリン誘導体 |
| JP5490778B2 (ja) | 2008-03-20 | 2014-05-14 | エナンタ ファーマシューティカルズ インコーポレイテッド | Ｃ型肝炎ウイルス阻害剤としてのフッ素化大環状化合物 |
| US8163921B2 (en) | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7964560B2 (en) | 2008-05-29 | 2011-06-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2300491B1 (en) | 2008-05-29 | 2016-01-06 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US8207341B2 (en) | 2008-09-04 | 2012-06-26 | Bristol-Myers Squibb Company | Process or synthesizing substituted isoquinolines |
| UY32099A (es) | 2008-09-11 | 2010-04-30 | Enanta Pharm Inc | Inhibidores macrocíclicos de serina proteasas de hepatitis c |
| US8563505B2 (en) | 2008-09-29 | 2013-10-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8044087B2 (en) | 2008-09-29 | 2011-10-25 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PL2364309T3 (pl) | 2008-12-10 | 2015-03-31 | Achillion Pharmaceuticals Inc | Nowe peptydy 4-amino-4-oksobutanoilowe jako inhibitory wirusowej replikacji |
| US8283310B2 (en) | 2008-12-15 | 2012-10-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CA2753667C (en) * | 2009-02-27 | 2015-11-17 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Amorphous salt of a macrocyclic inhibitor of hcv |
| WO2010118078A1 (en) | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Macrocyclic serine protease inhibitors |
| MA33330B1 (fr) * | 2009-05-29 | 2012-06-01 | Syngenta Participations Ag | Quinazolines substituées comme fongicides |
| TW201117812A (en) | 2009-08-05 | 2011-06-01 | Idenix Pharmaceuticals Inc | Macrocyclic serine protease inhibitors |
| EP2658859A4 (en) | 2010-12-30 | 2014-07-30 | Enanta Pharm Inc | MACROCYCLIC HEPATITIS C SERIN PROTEASE INHIBITORS |
| KR20140003521A (ko) | 2010-12-30 | 2014-01-09 | 이난타 파마슈티칼스, 인코포레이티드 | 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제 |
| AR085352A1 (es) | 2011-02-10 | 2013-09-25 | Idenix Pharmaceuticals Inc | Inhibidores macrociclicos de serina proteasa, sus composiciones farmaceuticas y su uso para tratar infecciones por hcv |
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013098313A1 (en) | 2011-12-28 | 2013-07-04 | Janssen R&D Ireland | Hetero-bicyclic derivatives as hcv inhibitors |
| MX348338B (es) * | 2012-10-15 | 2017-06-07 | Albemarle Corp | Procesos para la síntesis de 2-amino-4, 6-dimetoxibenzamida y otros compuestos de benzamida. |
| AU2012392557B2 (en) | 2012-10-19 | 2017-06-01 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2914613B1 (en) | 2012-11-02 | 2017-11-22 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2014070974A1 (en) | 2012-11-05 | 2014-05-08 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CN105164148A (zh) | 2013-03-07 | 2015-12-16 | 百时美施贵宝公司 | 丙型肝炎病毒抑制剂 |
| US9085607B2 (en) | 2013-03-15 | 2015-07-21 | Achillion Pharmaceuticals, Inc. | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof |
| WO2014145507A1 (en) | 2013-03-15 | 2014-09-18 | Achillion Pharmaceuticals, Inc. | A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof |
| WO2015103490A1 (en) | 2014-01-03 | 2015-07-09 | Abbvie, Inc. | Solid antiviral dosage forms |
| EP3108879A1 (en) | 2015-06-25 | 2016-12-28 | Cassiopea S.p.A. | High concentration formulation |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| UA74546C2 (en) * | 1999-04-06 | 2006-01-16 | Boehringer Ingelheim Ca Ltd | Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition |
| US6867185B2 (en) | 2001-12-20 | 2005-03-15 | Bristol-Myers Squibb Company | Inhibitors of hepatitis C virus |
| CA2481369C (en) | 2002-04-11 | 2012-07-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| US20050075279A1 (en) * | 2002-10-25 | 2005-04-07 | Boehringer Ingelheim International Gmbh | Macrocyclic peptides active against the hepatitis C virus |
| US20040180815A1 (en) * | 2003-03-07 | 2004-09-16 | Suanne Nakajima | Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
| AU2004211637C1 (en) * | 2003-02-07 | 2010-08-19 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
| US7173004B2 (en) * | 2003-04-16 | 2007-02-06 | Bristol-Myers Squibb Company | Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus |
| US7125845B2 (en) * | 2003-07-03 | 2006-10-24 | Enanta Pharmaceuticals, Inc. | Aza-peptide macrocyclic hepatitis C serine protease inhibitors |
| JP4704342B2 (ja) * | 2003-09-22 | 2011-06-15 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃ型肝炎ウイルスに対し活性な大環状ペプチド |
| WO2005073195A2 (en) * | 2004-01-30 | 2005-08-11 | Medivir Ab | Hcv ns-3 serine protease inhibitors |
| WO2007014921A1 (en) * | 2005-07-29 | 2007-02-08 | Tibotec Pharmaceuticals Ltd. | Macrocyclic inhibitors of hepatitis c virus |
| EP1910347A2 (en) * | 2005-07-29 | 2008-04-16 | Medivir Ab | Macrocylic inhibitors of hepatitis c virus |
| TWI383980B (zh) * | 2005-07-29 | 2013-02-01 | Tibotec Pharm Ltd | Ｃ型肝炎病毒之大環抑制劑 |
| PE20070211A1 (es) * | 2005-07-29 | 2007-05-12 | Medivir Ab | Compuestos macrociclicos como inhibidores del virus de hepatitis c |
-
2006
- 2006-07-26 PE PE2006000903A patent/PE20070343A1/es not_active Application Discontinuation
- 2006-07-28 EA EA200800482A patent/EA014188B1/ru not_active IP Right Cessation
- 2006-07-28 SI SI200630627T patent/SI1912981T1/sl unknown
- 2006-07-28 UY UY29704A patent/UY29704A1/es unknown
- 2006-07-28 EP EP06764268A patent/EP1912981B1/en active Active
- 2006-07-28 BR BRPI0614153-6A patent/BRPI0614153A2/pt not_active Application Discontinuation
- 2006-07-28 AU AU2006274866A patent/AU2006274866B2/en not_active Ceased
- 2006-07-28 WO PCT/EP2006/064822 patent/WO2007014927A2/en active Application Filing
- 2006-07-28 JP JP2008523383A patent/JP5230418B2/ja not_active Expired - Fee Related
- 2006-07-28 DK DK06764268.6T patent/DK1912981T3/da active
- 2006-07-28 KR KR1020087004894A patent/KR101083631B1/ko not_active IP Right Cessation
- 2006-07-28 AR ARP060103303A patent/AR057702A1/es not_active Application Discontinuation
- 2006-07-28 NZ NZ564540A patent/NZ564540A/en not_active IP Right Cessation
- 2006-07-28 US US11/995,900 patent/US7659245B2/en not_active Expired - Fee Related
- 2006-07-28 RS RSP-2010/0183A patent/RS51227B/sr unknown
- 2006-07-28 ES ES06764268T patent/ES2339702T3/es active Active
- 2006-07-28 PL PL06764268T patent/PL1912981T3/pl unknown
- 2006-07-28 ME MEP-2012-119A patent/ME01454B/me unknown
- 2006-07-28 GT GT200600343A patent/GT200600343A/es unknown
- 2006-07-28 TW TW095127585A patent/TWI387597B/zh not_active IP Right Cessation
- 2006-07-28 AP AP2008004306A patent/AP2585A/xx active
- 2006-07-28 AT AT06764268T patent/ATE455775T1/de active
- 2006-07-28 MY MYPI20063670 patent/MY151026A/en unknown
- 2006-07-28 CA CA2617103A patent/CA2617103C/en not_active Expired - Fee Related
- 2006-07-28 PT PT06764268T patent/PT1912981E/pt unknown
- 2006-07-28 DE DE602006011905T patent/DE602006011905D1/de active Active
- 2006-07-29 SV SV2006002641A patent/SV2008002641A/es unknown
-
2007
- 2007-12-20 IL IL188320A patent/IL188320A/en not_active IP Right Cessation
-
2008
- 2008-02-29 NO NO20081075A patent/NO20081075L/no not_active Application Discontinuation
- 2008-06-20 HK HK08106903.5A patent/HK1116488A1/xx not_active IP Right Cessation
-
2010
- 2010-04-14 HR HR20100209T patent/HRP20100209T1/hr unknown
- 2010-04-20 CY CY20101100355T patent/CY1110008T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20100209T1 (hr) | Makrociklički inhibitori virusa hepatitisa c | |
| HRP20100048T1 (hr) | Inhibitori hcv ns-3 serin proteaze | |
| NO20081071L (no) | Makrocykliske inhibitorer av hepatitt C virus | |
| HRP20181075T1 (hr) | Makrociklični inhibitori hepatitisa c serin proteaze | |
| JP2013514359A5 (me) | ||
| EP2041159B8 (en) | Macrocyclic compounds as antiviral agents | |
| SG161315A1 (en) | Compounds and methods for the treatment or prevention of flavivirus infections | |
| MY146123A (en) | Inhibitors of hepatitis c virus rna-dependent rna polymerase, and compositions and treatment using the same | |
| CU23787B7 (es) | Compuestos macrocíclicos como inhibidores de la replicación viral | |
| WO2011041713A3 (en) | Piperazinyl antiviral agents | |
| WO2021262826A3 (en) | 1'-cyano nucleoside analogs and uses thereof | |
| TW200745035A (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| UY28581A1 (es) | Compuestos nucleosidicos para el tratamiento de infecciones virales | |
| BR112014000563A2 (pt) | composto, composição farmacêutica, e, uso do composto | |
| NO20074613L (no) | Tricykliske nukleosidforbindelser for behandling av virale infeksjoner | |
| SG164376A1 (en) | Hcv ns3 protease inhibitors | |
| TW200602064A (en) | Nucleoside derivatives for treating hepatitis C virus infection | |
| TW200639169A (en) | Bicyclic heteroaryl derivatives for treating viruses | |
| TW200720285A (en) | Nucleoside compounds for treating viral infections | |
| DK1569929T3 (da) | Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner | |
| MX2012008443A (es) | Nucleosidos antiviricos. | |
| UA91255C2 (uk) | Антивірусні нуклеозиди | |
| JP2010521481A5 (me) | ||
| ATE455117T1 (de) | 5,6-dimethylthienoä2,3-diüpyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung für die bekämpfung von viren | |
| MX2012006513A (es) | Compuestos heterociclicos antivirales. |